Physician profile
John G Wideman
NPI 1336255728
$3,639.21
in general payments reported to CMS, 2019-2025
34 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $161 · 2021: $370 · 2022: $661 · 2023: $376 · 2024: $245 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,505.22 | 2019-2022 | |
| Abbvie INC. | $455.25 | 2019-2024 | Ubrelvy |
| Shield Therapeutics INC | $245.02 | 2023-2025 | Accrufer |
| Aspira Women'S Health INC | $215.50 | 2021-2022 | |
| Amgen INC. | $125.09 | 2019-2021 | |
| Myriad Women'S Health, INC. | $116.51 | 2023 | Myrisk |
| Boston Scientific Corporation | $76.06 | 2022 | |
| Organon LLC | $67.18 | 2022-2025 | Jada System, Nexplanon |
| Amag Pharmaceuticals, INC. | $59.89 | 2019-2020 | |
| Hologic Sales and Service, LLC | $55.98 | 2020-2023 | Aptima |
| Astellas Pharma US INC | $55.10 | 2023-2025 | Veozah |
| Scynexis, INC. | $53.18 | 2022 | |
| Avanos Medical | $52.43 | 2019-2023 | On-Q* Pump and Accessories |
| Duchesnay USA Incorporated | $51.78 | 2019 | |
| Siemens Medical Solutions USA, INC. | $50.90 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $46.77 | 2022-2023 | Slynd |
| Radius Health, INC. | $39.27 | 2019 | |
| Convatec INC. | $37.34 | 2022 | |
| Sage Therapeutics, LLC | $35.60 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $34.12 | 2023-2025 | |
| Becton, Dickinson and Company | $32.04 | 2019-2023 | Bd Onclarity |
| Evofem Biosciences, INC. | $31.62 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $27.20 | 2023 | Seglentis |
| Dexcom, INC. | $23.69 | 2025 | Dexcom G6 Transmitter |
| Covidien Lp | $18.85 | 2019 | |
| Axonics, INC. | $17.66 | 2023 | Axonics |
| Agile Therapeutics, INC. | $17.49 | 2021 | |
| Pharmacosmos Therapeutics INC. | $16.99 | 2021 | |
| Therapeuticsmd, INC. | $13.06 | 2019 | |
| Merck Sharp & Dohme LLC | $12.98 | 2020 | |
| Orexo US, INC. | $12.96 | 2021 | |
| Lupin INC. | $12.69 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $12.09 | 2020 | |
| Ascend Therapeutics US, LLC | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wideman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.